Bovine respiratory disease (BRD) is one of the leading causes of death in pre-weaned calves and weaned dairy heifers (15). It has been difficult to develop effective control strategies because the disease is multifactorial, but vaccination can help reduce the risk of this disease (14). Previous studies have reported that booster vaccinations with a commercially available inactivated
When young children are vaccinated, the doses are frequently lower than when adults are vaccinated (3, 11). According to Qadri
Voysey
A previous study (6) reported that a satisfactory body mass index (BMI) was positively correlated with antibody production following administration of the inactivated vaccine in young Holstein calves. It is therefore necessary to ensure that the BMI at the time of vaccination is similar between groups to study the effect of dosage.
In this study we present antibody responses in young Holstein calves matched for BMI receiving a dose of 1.0 mL or of 0.5 mL of the inactivated
For this study, 66 healthy female Holstein calves on a commercial dairy farm were selected as subjects. Veterinarians from the Rakuno Gakuen University Animal Medical Center’s Large Animal Clinical Services team regularly visited this farm and vaccinated the calves. All procedures described in this study were conducted and all necessary animal care was given in accordance with the guidelines of the Rakuno Gakuen University Animal Experiment and Care Committee. Verbal informed consent from the herd’s owner was obtained for the field experiment and the Rakuno Gakuen University Animal Experiment and Care Committee approved the acceptability of such a form of consent.
All calves were born on the farm and were separated from their dams within 12 h of birth. Calves received adequate amounts of colostrum replacer (Calfsupport Dash, Zenoaq, Fukushima, Japan) and were reared in isolation in hutches. Three experimental groups each of 14 calves and two control groups each of 12 calves were created. One experimental group was administered 1.0 mL of the vaccine as the primary vaccination and 1.0 mL as the booster. Another experimental group was administered 0.5 mL of the vaccine as the primary vaccination and 1.0 mL as the booster. The final experimental group was administered 0.5 mL of the vaccine as the primary vaccination and 0.5 mL as the booster. A 20 mL vial of vaccine contained inactivated whole bacterial cells of
Dosages of the vaccine and sample size
Group | Dose at one week of age | Dose at four weeks of age | Sample size |
---|---|---|---|
1.0 + 1.0 | 1.0 mL | 1.0 mL | n = 14 |
0.5 + 1.0 | 0.5 mL | 1.0 mL | n = 14 |
0.5 + 0.5 | 0.5 mL | 0.5 mL | n = 14 |
PV-Control | Not vaccinated | 1.0 mL | n = 12 |
NV-Control | Not vaccinated | Not vaccinated | n = 12 |
PV-Control – primary-vaccination control; NV-Control – no-vaccination control
The body weights and withers heights of the calves were measured on the day of primary vaccination (experimental group) or at one week of age (control group), and each calf’s BMI was calculated by dividing the body weight in kilograms by the square of the height in metres (16).
Blood was drawn immediately before each vaccination and again three weeks later. Sampling was on the same day as when the calves were weighed (at one week of age) in the PV- and NV-Control groups and was additionally performed at four and seven weeks of age in the NV-Control group. To isolate the serum, blood samples were collected into plain vacutainer tubes and centrifuged at 3,500 rpm for 8 min. The serum was stored at -30°C until the analysis, and the antibodies to
The data were expressed as geometric mean ± standard error of the mean. All analyses were carried out using XLSTAT 2021.3.1 (Addinsoft, Paris, France). The Kruskal–Wallis and the Dwass–Steel– Critchlow–Fligner tests were used to compare antibody titres and BMIs between groups. Differences between titres at primary vaccination (or one week of age), booster vaccination (or four weeks) and three weeks after final vaccination (or seven weeks) were examined using the Friedman and Nemenyi tests. Fisher’s exact test of independence was used to compare the number of calves with positive and negative vaccine responses or the number of calves with high and low MAL. In experimental groups of calves, multivariable logistic regression was used to examine the relationship between dosage and seropositivity for
Table 2 shows the BMIs of the calves at the time of primary vaccination. There were slight differences between groups (P = 0.286). The P-values between groups for the BMI parameter are also shown in Table 2.
Body mass index (BMI) values for the experimental and control groups of young Holstein calves and null hypothesis validity of the values
Group | BMI | P-value | ||||
---|---|---|---|---|---|---|
1.0 + 1.0 | 0.5 + 1.0 | 0.5 + 0.5 | PV-Control | NV-Control | ||
1.0 + 1.0 | 64.9 ± 0.8 | 1 | 0.898 | 1.000 | 0.731 | 0.715 |
0.5 + 1.0 | 64.0 ± 0.9 | 0.898 | 1 | 0.975 | 0.568 | 0.534 |
0.5 + 0.5 | 64.6 ± 0.8 | 1.000 | 0.975 | 1 | 0.731 | 0.584 |
PV-Control | 66.8 ± 1.5 | 0.731 | 0.568 | 0.731 | 1 | 0.999 |
NV-Control | 66.8 ± 1.7 | 0.715 | 0.534 | 0.584 | 0.999 | 1 |
PV-Control – primary-vaccination control; NV-Control – no-vaccination control
Figure 1 depicts antibody responses in young Holstein calves following early vaccination with the inactivated bacterial preparation. Calves in all three experimental groups exhibited significantly increased titres of anti-
Antibody responses in young Holstein calves vaccinated with a dose of 1.0 mL or 0.5 mL of an inactivated bacterial vaccine against bovine respiratory disease PV-Control - primary-vaccination control; NV-Control - no-vaccination control; arrows – vaccination times; **, * – significant increase compared to titre at one week of age (P < 0.01, P < 0.05); †† – significant decrease compared to titre at one week of age (P < 0.01); A-B, X-Y, a-b, x-y, α-β, χ-ψ – differences in final antibody titres (P < 0.01, P < 0.01, P < 0.05, P < 0.05, P < 0.10, and P < 0.10, respectively)
The numbers of calves with high and low MAL and those with positive and negative vaccine responses are shown in Table 3. Although there was generally no significant difference between groups in the number of calves with high and low MAL, there tended to be a difference in the number of calves with high and low MAL against
The number of calves with high and low maternal antibody levels and with positive and negative vaccine responses to (a)
(a) | One week of age | Seven weeks of age | ||||
---|---|---|---|---|---|---|
High MAL | Low MAL | P-value | Positive | Negative | P-value | |
1.0 + 1.0 | 0 | 14 | − | 11 | 3 | 0.005** |
0.5 + 1.0 | 0 | 14 | − | 12 | 2 | 0.000** |
0.5 + 0.5 | 0 | 14 | − | 5 | 9 | 0.556 |
PV-Control | 0 | 12 | − | 1 | 11 | 0.008** |
NV-Control | 0 | 12 | − | 0 | 12 | 0.000** |
P-value | 1.000 | 0.000** | ||||
(b) | One week of age | Seven weeks of age | ||||
High MAL | Low MAL | P-value | Positive | Negative | P-value | |
1.0 + 1.0 | 9 | 5 | − | 14 | 0 | 0.015* |
0.5 + 1.0 | 4 | 10 | − | 14 | 0 | 0.015* |
0.5 + 0.5 | 6 | 8 | − | 13 | 1 | 0.159 |
PV-Control | 7 | 5 | − | 5 | 7 | 0.006** |
NV-Control | 6 | 6 | − | 4 | 8 | 0.000** |
P-value | 0.402 | 0.000** | ||||
(c) | One week of age | Seven weeks of age | ||||
High MAL | Low MAL | P-value | Positive | Negative | P-value | |
1.0 + 1.0 | 9 | 5 | − | 2 | 12 | − |
0.5 + 1.0 | 6 | 8 | − | 3 | 11 | − |
0.5 + 0.5 | 12 | 2 | − | 2 | 12 | − |
PV-Control | 5 | 7 | − | 0 | 12 | − |
NV-Control | 6 | 6 | − | 0 | 12 | − |
P-value | 0.104 | 0.275 |
Antibody titres greater than 0.604 (
– P < 0.01,
– P < 0.05
The standardised regression coefficients from the logistic regression analysis for seropositivity in experimental group calves are shown in Fig. 2. Although the dose of the booster vaccination was positively correlated with seropositivity for
Standardised regression coefficients from the logistic regression for seropositivity Primary – primary vaccination; Booster – booster vaccination; * – P < 0.05
Recent studies have found that young calves receiving an inactivated commercial bacterial vaccine have higher antibody titres and can mount an effective immune defence against BRD (5, 9). The appropriate dosage of this vaccine in young calves, however, had been little studied prior to the present research. In this study, we investigated antibody response in young Holstein calves which received 0.5 mL or 1.0 mL of the vaccine in the field.
This study revealed that calves in all experimental groups showed increased antibodies against
Conversely, the 0.5 + 0.5 group had a lower number of
Antibody titres also increased at some points in the control groups. The antigens in the vaccines were known as bacterial elements of the nasal microbiome (1), and it cannot be ruled out that there was antigenic stimulation from the bacteria present in the control animals’ nasal cavities. However, as all calves in this study were born on the same farm and only healthy calves were used, we believe that antigen stimulation by normal intranasal flora was generally equal between groups. A field trial using the same vaccine and methods has been reported (5). It is contended that the increased antibody titres after vaccination were due to both the antigenic stimulation by the bacterial flora and vaccination.
In this study, however, the number of calves with positive vaccine responses to
In conclusion, we propose that a dose of 0.5 mL can be administered for primary vaccination with this commercial BRD prophylactic in newborn Holstein calves aged one week, but the dose of 1.0 mL may be required for the booster vaccination. Vaccine response, however, may differ depending on the BMI, the week of age and the breed. Further studies are justified to confirm the comparable immunogenicity and effectiveness of the doses of 1.0 mL and 0.5 mL for primary vaccination in young calves.